Notice from Samsung Biologics in Relation to its Designation as a Company that Has Failed to Comply with Public Disclosure Requirements
Notice from Samsung Biologics in Relation to its Designation as a Company that Has Failed to Comply with Public Disclosure Requirements
Following the close of the trading session on April 5, 2017, we received official notice from the Korea Exchange (KRX) designating Samsung Biologics as a company that has failed to comply with the public disclosure requirements on the basis of our delayed public disclosure (which was made on March 13, 2017) of Samsung Bioepis' audited financial statements (public disclosure was due to be made by February 28, 2017).
The above notice relates to the ‘Preliminary Notice of Designation of a Company that Has Failed to Comply with Public Disclosure Requirements’ that we posted on our website at the following link on March 13, 2017:
In connection with the above designation, the Korea Exchange assessed no penalty points but only imposed a fine in the amount of KRW 8 million for violating the public disclosure requirements.
Going forward, Samsung Biologics will further reinforce its internal training system and management process for employees responsible for public disclosure.
Notice from Samsung Biologics in Relation to its Designation as a Company that Has Failed to Comply with Public Disclosure Requirements
Following the close of the trading session on April 5, 2017, we received official notice from the Korea Exchange (KRX) designating Samsung Biologics as a company that has failed to comply with the public disclosure requirements on the basis of our delayed public disclosure (which was made on March 13, 2017) of Samsung Bioepis' audited financial statements (public disclosure was due to be made by February 28, 2017).
The above notice relates to the ‘Preliminary Notice of Designation of a Company that Has Failed to Comply with Public Disclosure Requirements’ that we posted on our website at the following link on March 13, 2017:
In connection with the above designation, the Korea Exchange assessed no penalty points but only imposed a fine in the amount of KRW 8 million for violating the public disclosure requirements.
Going forward, Samsung Biologics will further reinforce its internal training system and management process for employees responsible for public disclosure.
Share article
Related Content